These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2568040)

  • 41. [Physico-chemical and serological study of agglutinogen 3 of B. pertussis].
    Amelina IP
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Feb; (2):64-7. PubMed ID: 178126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of fimbrial subunits from Bordetella species.
    Mooi FR; van der Heide HG; ter Avest AR; Welinder KG; Livey I; van der Zeijst BA; Gaastra W
    Microb Pathog; 1987 Jun; 2(6):473-84. PubMed ID: 2907088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of spheroplast-derived strains to differentiate between Bordetella pertussis heat-labile agglutinogens and protective antigen for mice.
    Dolby JM; Bronne-Shanbury CJ
    J Biol Stand; 1975; 3(1):89-100. PubMed ID: 165202
    [No Abstract]   [Full Text] [Related]  

  • 44. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
    Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
    Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell surface antigens of Bordetella pertussis.
    Parker CD; Branes LV; Armstrong SK; Frank DW; Cole A
    Dev Biol Stand; 1985; 61():123-36. PubMed ID: 2872098
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species.
    Munoz JJ; Peacock MG
    Microbiol Immunol; 1989; 33(4):341-55. PubMed ID: 2549344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immuno-electronmicroscopy of fimbriae-like structures on Bordetella pertussis serotype 1.3.
    Fredriksen JH; Namork E; Frøholm LO
    J Med Microbiol; 1988 Apr; 25(4):285-8. PubMed ID: 2895814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Studies on a method for the assay of antibody to Bordetella pertussis fimbrial hemagglutinin after inoculation with pertussis HA vaccine (author's transl)].
    Murase Y
    Kansenshogaku Zasshi; 1981 Jul; 55(7):511-23. PubMed ID: 6120200
    [No Abstract]   [Full Text] [Related]  

  • 50. Purification and preliminary characterization of agglutinogen 3 from Bordetella pertussis.
    Fredriksen JH; Frøholm LO; Paulsen BS
    Dev Biol Stand; 1985; 61():187-96. PubMed ID: 2872104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The location of surface antigens of Bordetella pertussis by immuno-electron microscopy.
    Ashworth LA; Dowsett AB; Irons LI; Robinson A
    Dev Biol Stand; 1985; 61():143-51. PubMed ID: 2872100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase-shift markers in Bordetella: alterations in envelope proteins.
    Ezzell JW; Dobrogosz WJ; Kloos WE; Manclark CR
    J Infect Dis; 1981 Apr; 143(4):562-9. PubMed ID: 6263983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Isolation and properties of the leukocytosis- and lymphocytosis-promoting factor of Bordetella pertussis.
    Morse SI; Morse JH
    J Exp Med; 1976 Jun; 143(6):1483-502. PubMed ID: 58054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis.
    Arciniega JL; Hewlett EL; Johnson FD; Deforest A; Wassilak SG; Onorato IM; Manclark CR; Burns DL
    J Infect Dis; 1991 Jan; 163(1):135-42. PubMed ID: 1984460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High prevalence of currently circulating Bordetella pertussis isolates not producing vaccine antigen pertactin in Slovenia.
    Kastrin T; Barkoff AM; Paragi M; Vitek MG; Mertsola J; He Q
    Clin Microbiol Infect; 2019 Feb; 25(2):258-260. PubMed ID: 30691616
    [No Abstract]   [Full Text] [Related]  

  • 56. [Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].
    Shinkarev AS; Mertsalova NU; Mazurova IK; Borisova OIu; Zakharova NS; Ozeretskovskaia MN; Zaĭtsev EM; Poddubikov AV; Britsina MV; Bazhanova IG
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):20-5. PubMed ID: 17886371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surface proteins of Bordetella pertussis.
    Parker CD; Armstrong SK
    Rev Infect Dis; 1988; 10 Suppl 2():S327-30. PubMed ID: 2903539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Formulation and characterisation of Bordetella pertussis fimbriae as novel carrier proteins for Hib conjugate vaccines.
    Crowley-Luke A; Reddin K; Gorringe A; Hudson MJ; Robinson A
    Vaccine; 2001 May; 19(25-26):3399-407. PubMed ID: 11348704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rabbit nasopharyngeal colonization by Bordetella pertussis: the effects of immunization on clearance and on serum and nasal antibody levels.
    Ashworth LA; Fitzgeorge RB; Irons LI; Morgan CP; Robinson A
    J Hyg (Lond); 1982 Jun; 88(3):475-86. PubMed ID: 6282959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of pooled and individual components of Bordetella pertussis as antigens in an enzyme immunoassay for diagnosis of pertussis.
    He Q; Mertsola J; Himanen JP; Ruuskanen O; Viljanen MK
    Eur J Clin Microbiol Infect Dis; 1993 Sep; 12(9):690-5. PubMed ID: 8243485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.